AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Eli Lilly

Regeneron Pharmaceuticals

Vir Biotechnology

Here's how several leading COVID-19 antibody therapies compare based on pre-clinical testing.

These COVID Therapies Appear to Be the Best and Worst at Treating New Variants

The big drugmaker now faces another challenge for its COVID-19 vaccine.

Why a Top European Official Is Warning to Avoid AstraZeneca's COVID Vaccine

Serum Institute of India's (SII) CEO Adar Poonawalla said he was trying to resolve EU travel problems facing Indians inoculated with SII's licensed version of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine. "I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries," Poonawalla said on Twitter.

India Made AstraZeneca's COVID-19 Vaccine Not Eligible For EU Travel, Seeks Resolution: Reuters

The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of chronic kidney disease in adults with and without type-II diabetes.

AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Kidney Disease

A sub-analysis from the Oxford-led COV001 and COV002 trials with AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine induced strong immune responses following a prolonged second dose interval to 45 weeks (10 months) or following a third boosting dose. The researchers were also able to show that a booster given more than six months after the second dose induced a strong response and increased activity against variants.

AstraZeneca COVID-19 Vaccine Shows Higher Immune Response With Longer Gap, Third Booster Dose

A third dose of the AstraZeneca vaccine more than six months after the second could boost protection against COVID-19, an Oxford University study has found.

Third dose of AstraZeneca COVID-19 vaccine boosts immune response, Oxford study finds

AstraZeneca Plc (NASDAQ: AZN) has started testing its new COVID vaccine, dubbed AZD2816, a tweaked version using the same platform as its authorized (though not in the U.S.) vaccine AZD1222, aka Covishield/Vaxzevria. AZD2816 has been built using the same adenoviral vector platform as its existing shot, with minor genetic alterations to the spike protein-based specifically on the so-called beta (B.1.351, South African) variant.

AstraZeneca Kick-Starts New COVID-19 Variant Vaccine Trial

AstraZeneca Plc (NASDAQ: AZN) announced data from the MEDLEY Phase 2/3 trial evaluating nirsevimab in infants at high risk of respiratory syncytial virus (RSV). The trial assessed the safety and tolerability of nirsevimab compared to Sobi's Synagis (palivizumab) in infants with chronic lung disease, congenital heart disease, and/or prematurity.

AstraZeneca's Nirsevimab Shows Favorable Safety, Tolerability Profile In Infants At High Risk Of RSV

AstraZeneca Plc (NASDAQ: AZN) has reported results from the Phase 3 trial evaluating exenatide extended-release 2mg in adolescents aged 10–17 years with type 2 diabetes. This once-weekly glucagon-like peptide-1 receptor agonist significantly reduced blood sugar, as measured by HbA1c, versus placebo.

AstraZeneca's Type 2 Diabetes Treatment Shows Clinical Benefit In Adolescents

AstraZeneca's (AZN) Koselugo becomes the first medicine approved in Europe for neurofibromatosis type 1 plexiform neurofibromas.

AstraZeneca (AZN) Rare Disorder Drug Koselugo Gets EU Nod

CureVac B.V

Moderna

Pfizer

Bad news for AstraZeneca and CureVac should mean more good news for Pfizer and Moderna.

How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's Challenges

AstraZeneca PLC (LON:AZN) said the COVID-19 vaccine developed with Oxford University is effective against the Delta and Kappa variant, which were first found in India. The FTSE 100 cited a study by the university built on an analysis by the Public Health England (PHE), Reuters reported.

AstraZeneca says COVID-19 vaccine effective against Delta variant

European Union has approved AstraZeneca plc's (NASDAQ: AZN) Koselugo to treat children with neurofibromatosis type 1 and plexiform neurofibromas. Neurofibromatosis type 1 is characterized by soft lumps on and under the skin and skin pigmentation.

AstraZeneca's Koselugo Gets European Nod To Treat Children With Multisystem Genetic Disorder

AstraZeneca PLC (LON:AZN) announced that its candidate Koselugo (selumetinib), developed with Merck & Co., Inc. (NYSE:MRK) has been granted conditional approval in the EU. Koselugo has been designed to treat symptomatic, inoperable nerve tumours in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above.

AstraZeneca receives EU approval for nerve cancer therapy for kids

A court in Brussels orders AstraZeneca (AZN) to supply 80 million doses of its COVID-19 vaccine to Europe by Sep 27, 2021. The European Commission had requested for 300 million doses by end of September.

AstraZeneca (AZN) Gets Court Order to Supply COVID-19 Jabs in EU

Johnson & Johnson

Emergent BioSolutions also ruined at least 15 million doses of Johnson & Johnson's COVID-19 vaccine earlier this year.

The US is scrambling to send promised vaccines abroad after the same production plant that ruined millions of J&J vaccines also taints AstraZeneca shots

The European Commission had taken AstraZeneca to court accusing it of failing to honor its contract to deliver Covid-19 vaccine doses.

Court Rules on EU and AstraZeneca Dispute Over Vaccine Supplies. Here's the Verdict.

AstraZeneca PLC (LON:AZN) has won a legal battle against the European Union's executive branch after the bloc attempted to force the pharma giant to deliver millions of doses of its coronavirus (COVID-19) vaccine or face large fines. On Friday, the FTSE 100 company said the EU's Court of First Instance in Brussels had ruled that the European Commission (EC) “has no exclusivity or right of priority over all other contracting parties” while also acknowledging that the difficulties experienced by AstraZeneca during the “unprecedented situation” of the pandemic had had “a substantial impact on the delay”.

AstraZeneca wins legal battle with EU over COVID-19 vaccine deliveries

AstraZeneca , the British-Swedish pharmaceutical group and developer of the world's most used COVID-19 vaccine, had a positive outcome in a court case brought by the European Union over its contract to deliver vaccine to the bloc. The European Commission, the EU's executive body, had requested 120 million vaccine doses cumulatively by the end of June 2021, and a total of 300 million doses by the end of September 2021.

AstraZeneca says EU defeated in legal bid over vaccine supplies

AstraZeneca Plc (NASDAQ: AZN) claims victory in a court tussle with the European Union over allegations that the company was not producing shots fast enough, thus missing COVID-19 vaccine deliveries. The company had planned 120 million vaccine doses cumulatively by the end of June 2021 and 300 million doses by the end of September.

Court Rules In Favor Of AstraZeneca Over Delay In COVID-19 Shot Deliveries

The availability of other vaccines and Australia's low case rate changed the cost-benefit calculation for those taking the vaccine, officials said.

Australia Restricts AstraZeneca Covid Shot In Over 60s Over Blood Clot Risks, Joining Italy, Greece And Others

OSLO, Norway, June 17, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that the ONCOS-102 and durvalumab trial in patients with advanced peritoneal malignancies has completed enrollment in the colorectal cancer cohort.   This phase 1/2 trial investigates the safety, biologic and anti-tumor activity of ONCOS-102 in combination with Imfinzi (durvalumab, anti-PD-L1) in patients with advanced peritoneal malignancies who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian or colorectal cancer.

Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies

AstraZeneca's (AZN) antibody cocktail, AZD7442 fails to prevent people who were already infected from developing symptomatic COVID-19. However, it showed some efficacy in people who were not infected.

AstraZeneca (AZN) Antibody Cocktail Fails to Prevent COVID-19

AstraZeneca has frequently attracted negative headlines in relation to its COVID vaccine, Vaxzevria, centered around safety, efficacy and distribution issues.

AstraZeneca: Forget Its Vaccine Woes, It Is A Solid Buy

AstraZeneca plc (LON:AZN) released its ‘Storm Chaser' study results on Tuesday that at first glance appear disappointing but beyond the headline takeaway, there were some positives. The trial assessed both the efficacy and safety of the LAAB (long-acting antibody) combination, AZD7442, designed to battle the SARS-CoV-2 virus.

News for AstraZeneca Stock (AZN)